Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells

Ugur Uslu, Stefan Schliep, Klaus Schliep, Michael Erdmann, Hans-Uwe Koch, Hans Parsch, Stina Rosenheinrich, Doris Anzengruber, Anja Katrin Bosserhoff, Gerold Schuler, Beatrice Schuler-Thurner

Research output: Contribution to journalArticleResearchpeer-review

Abstract

BACKGROUND: In patients with melanoma, early dissemination via lymphatic and hematogenous routes is frequently seen. Thus, besides clinical follow-up examination and imaging, reliable melanoma-specific serological tumor markers are needed.

PATIENTS AND METHODS: We retrospectively compared two serum markers for melanoma, S100 and melanoma-inhibitory activity (MIA), for monitoring of patients with metastatic melanoma under either adjuvant or therapeutic vaccination immunotherapy with dendritic cells (DC). Serum was obtained from a total of 100 patients (28 patients in stage III and 72 patients in stage IV, according to the American Joint Committee on Cancer 2002) at regular intervals during therapy, accompanied by follow-up imaging.

RESULTS: When relapse was detected, both markers often remained within normal range. In contrast, in patients with metastatic measurable disease receiving therapeutic and not adjuvant DC vaccination, an increase of both markers was a strong indicator for disease progression. When comparing both markers in the whole study population, MIA showed a superior sensitivity to detect disease progression.

CONCLUSION: S100 and MIA are highly sensitive tumor markers for monitoring of patients with melanoma with current metastases, but less sensitive for monitoring of tumor-free patients. In the current study, MIA had a slightly superior sensitivity to detect progressive disease compared to S100 and seems to be more useful in monitoring of patients with metastatic melanoma receiving immunotherapy.

Original languageEnglish
Pages (from-to)5033-5037
Number of pages5
JournalAnticancer Research
Volume37
Issue number9
DOIs
Publication statusPublished - Sep 2017
Externally publishedYes

Fingerprint

Physiologic Monitoring
Tumor Biomarkers
Immunotherapy
Dendritic Cells
Melanoma
Vaccination
Biomarkers
Disease Progression
Neoplasms
Reference Values
Therapeutics
Neoplasm Metastasis
Recurrence

Keywords

  • Biomarkers, Tumor/blood
  • Dendritic Cells/immunology
  • Disease Progression
  • Extracellular Matrix Proteins/blood
  • Female
  • Humans
  • Immunotherapy
  • Male
  • Melanoma/blood
  • Neoplasm Proteins/blood
  • Neoplasm Staging
  • S100 Proteins/blood
  • Skin Neoplasms/blood
  • Vaccination

Cite this

Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells. / Uslu, Ugur; Schliep, Stefan; Schliep, Klaus; Erdmann, Michael; Koch, Hans-Uwe; Parsch, Hans; Rosenheinrich, Stina; Anzengruber, Doris; Bosserhoff, Anja Katrin; Schuler, Gerold; Schuler-Thurner, Beatrice.

In: Anticancer Research, Vol. 37, No. 9, 09.2017, p. 5033-5037.

Research output: Contribution to journalArticleResearchpeer-review

Uslu, U, Schliep, S, Schliep, K, Erdmann, M, Koch, H-U, Parsch, H, Rosenheinrich, S, Anzengruber, D, Bosserhoff, AK, Schuler, G & Schuler-Thurner, B 2017, 'Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells' Anticancer Research, vol. 37, no. 9, pp. 5033-5037. https://doi.org/10.21873/anticanres.11918
Uslu, Ugur ; Schliep, Stefan ; Schliep, Klaus ; Erdmann, Michael ; Koch, Hans-Uwe ; Parsch, Hans ; Rosenheinrich, Stina ; Anzengruber, Doris ; Bosserhoff, Anja Katrin ; Schuler, Gerold ; Schuler-Thurner, Beatrice. / Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells. In: Anticancer Research. 2017 ; Vol. 37, No. 9. pp. 5033-5037.
@article{06e0ab08511d49a5845285f5198bfaf3,
title = "Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells",
abstract = "BACKGROUND: In patients with melanoma, early dissemination via lymphatic and hematogenous routes is frequently seen. Thus, besides clinical follow-up examination and imaging, reliable melanoma-specific serological tumor markers are needed.PATIENTS AND METHODS: We retrospectively compared two serum markers for melanoma, S100 and melanoma-inhibitory activity (MIA), for monitoring of patients with metastatic melanoma under either adjuvant or therapeutic vaccination immunotherapy with dendritic cells (DC). Serum was obtained from a total of 100 patients (28 patients in stage III and 72 patients in stage IV, according to the American Joint Committee on Cancer 2002) at regular intervals during therapy, accompanied by follow-up imaging.RESULTS: When relapse was detected, both markers often remained within normal range. In contrast, in patients with metastatic measurable disease receiving therapeutic and not adjuvant DC vaccination, an increase of both markers was a strong indicator for disease progression. When comparing both markers in the whole study population, MIA showed a superior sensitivity to detect disease progression.CONCLUSION: S100 and MIA are highly sensitive tumor markers for monitoring of patients with melanoma with current metastases, but less sensitive for monitoring of tumor-free patients. In the current study, MIA had a slightly superior sensitivity to detect progressive disease compared to S100 and seems to be more useful in monitoring of patients with metastatic melanoma receiving immunotherapy.",
keywords = "Biomarkers, Tumor/blood, Dendritic Cells/immunology, Disease Progression, Extracellular Matrix Proteins/blood, Female, Humans, Immunotherapy, Male, Melanoma/blood, Neoplasm Proteins/blood, Neoplasm Staging, S100 Proteins/blood, Skin Neoplasms/blood, Vaccination",
author = "Ugur Uslu and Stefan Schliep and Klaus Schliep and Michael Erdmann and Hans-Uwe Koch and Hans Parsch and Stina Rosenheinrich and Doris Anzengruber and Bosserhoff, {Anja Katrin} and Gerold Schuler and Beatrice Schuler-Thurner",
note = "Copyright{\circledC} 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.",
year = "2017",
month = "9",
doi = "10.21873/anticanres.11918",
language = "English",
volume = "37",
pages = "5033--5037",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "9",

}

TY - JOUR

T1 - Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells

AU - Uslu, Ugur

AU - Schliep, Stefan

AU - Schliep, Klaus

AU - Erdmann, Michael

AU - Koch, Hans-Uwe

AU - Parsch, Hans

AU - Rosenheinrich, Stina

AU - Anzengruber, Doris

AU - Bosserhoff, Anja Katrin

AU - Schuler, Gerold

AU - Schuler-Thurner, Beatrice

N1 - Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

PY - 2017/9

Y1 - 2017/9

N2 - BACKGROUND: In patients with melanoma, early dissemination via lymphatic and hematogenous routes is frequently seen. Thus, besides clinical follow-up examination and imaging, reliable melanoma-specific serological tumor markers are needed.PATIENTS AND METHODS: We retrospectively compared two serum markers for melanoma, S100 and melanoma-inhibitory activity (MIA), for monitoring of patients with metastatic melanoma under either adjuvant or therapeutic vaccination immunotherapy with dendritic cells (DC). Serum was obtained from a total of 100 patients (28 patients in stage III and 72 patients in stage IV, according to the American Joint Committee on Cancer 2002) at regular intervals during therapy, accompanied by follow-up imaging.RESULTS: When relapse was detected, both markers often remained within normal range. In contrast, in patients with metastatic measurable disease receiving therapeutic and not adjuvant DC vaccination, an increase of both markers was a strong indicator for disease progression. When comparing both markers in the whole study population, MIA showed a superior sensitivity to detect disease progression.CONCLUSION: S100 and MIA are highly sensitive tumor markers for monitoring of patients with melanoma with current metastases, but less sensitive for monitoring of tumor-free patients. In the current study, MIA had a slightly superior sensitivity to detect progressive disease compared to S100 and seems to be more useful in monitoring of patients with metastatic melanoma receiving immunotherapy.

AB - BACKGROUND: In patients with melanoma, early dissemination via lymphatic and hematogenous routes is frequently seen. Thus, besides clinical follow-up examination and imaging, reliable melanoma-specific serological tumor markers are needed.PATIENTS AND METHODS: We retrospectively compared two serum markers for melanoma, S100 and melanoma-inhibitory activity (MIA), for monitoring of patients with metastatic melanoma under either adjuvant or therapeutic vaccination immunotherapy with dendritic cells (DC). Serum was obtained from a total of 100 patients (28 patients in stage III and 72 patients in stage IV, according to the American Joint Committee on Cancer 2002) at regular intervals during therapy, accompanied by follow-up imaging.RESULTS: When relapse was detected, both markers often remained within normal range. In contrast, in patients with metastatic measurable disease receiving therapeutic and not adjuvant DC vaccination, an increase of both markers was a strong indicator for disease progression. When comparing both markers in the whole study population, MIA showed a superior sensitivity to detect disease progression.CONCLUSION: S100 and MIA are highly sensitive tumor markers for monitoring of patients with melanoma with current metastases, but less sensitive for monitoring of tumor-free patients. In the current study, MIA had a slightly superior sensitivity to detect progressive disease compared to S100 and seems to be more useful in monitoring of patients with metastatic melanoma receiving immunotherapy.

KW - Biomarkers, Tumor/blood

KW - Dendritic Cells/immunology

KW - Disease Progression

KW - Extracellular Matrix Proteins/blood

KW - Female

KW - Humans

KW - Immunotherapy

KW - Male

KW - Melanoma/blood

KW - Neoplasm Proteins/blood

KW - Neoplasm Staging

KW - S100 Proteins/blood

KW - Skin Neoplasms/blood

KW - Vaccination

U2 - 10.21873/anticanres.11918

DO - 10.21873/anticanres.11918

M3 - Article

VL - 37

SP - 5033

EP - 5037

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 9

ER -